Nabi Biopharmaceuticals (NABI) (JOBS), GlaxoSmithKline (GSK) (JOBS) Sign Nicotine Addiction Vaccine Deal; Nabi Will Get $40 Million Upfront and is Eligible for More Than $500 Million
11/16/2009 6:43:44 AM
More...
|
Nabi Biopharmaceuticals (NABI) Announces Third Quarter 2009 Financial Results
11/6/2009 8:54:31 AM
More...
|
Nabi Biopharmaceuticals (NABI) Announces Withdrawal of Biotest Pharmaceuticals's Indemnification Claim
11/4/2009 8:40:15 AM
More...
|
Nabi Biopharmaceuticals (NABI) Completes Sale of PentaStaph(TM) to GlaxoSmithKline (GSK)
11/4/2009 8:25:27 AM
More...
|
Nabi Biopharmaceuticals (NABI) Initiates Pivotal Phase III Study for NicVAX as an Aid to Smoking Cessation and Long-term Abstinence
11/3/2009 8:30:27 AM
More...
|
Nabi Biopharmaceuticals (NABI) Participates in NicVAX(R) Phase IIb Study
10/28/2009 8:20:10 AM
More...
|
Nabi Biopharmaceuticals (NABI) to Announce Third Quarter Financial Results on November 5, 2009
10/27/2009 11:39:39 AM
More...
|
Nabi Biopharmaceuticals (NABI) Land $10 Million for Smoking Cessation Trials
9/30/2009 8:32:37 AM
More...
|
Nabi Biopharmaceuticals (NABI) Receives Grant Supporting Further NicVAX Development
9/29/2009 9:12:40 AM
More...
|
Nabi Biopharmaceuticals (NABI) to Present At Rodman & Renshaw's Annual Global Investment Conference
9/2/2009 9:15:49 AM
More...
|
|